Retrospective Analysis of Patients Treated With Bevacizumab in GHPSJ Intraperitoneal for the Treatment of Refractory Malignant Ascites
Latest Information Update: 24 Aug 2023
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary)
- Indications Malignant ascites
- Focus Therapeutic Use
- Acronyms BEVASCITE
- 23 Sep 2016 New trial record